Comparative study between corticosteroids and colchicine effect on interleukin-6 and Krebs-von-den Lungen-6 in treatment of post covid pulmonary fibrosis

Author:

Bedir Mohamed A. E. G.1,Elemery Fawzy A. E.1,Elghafar Mohamed T. A.2,Torky Mohamed1

Affiliation:

1. Departments of Chest, Faculty of Medicine, Tanta University, Tanta, Egypt

2. Departments of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt

Abstract

Background Interstitial lung diseases (ILDs) involve a diverse range of over 200 lung disorders, constituting a vast group of diseases. This study aimed to compare Corticosteroids and Colchicine in the treatment of post-covid pulmonary fibrosis (PC19-PF) through the assessment of effects of these drugs on some biomarkers as interleukin-6 (IL6) and Krebs-von-den Lungen-6 (KL6). Method This randomized controlled study was carried out 30 patients with PC19-PF and 10 healthy volunteers. All patients were randomly classified into four equal groups: group 1: received corticosteroids in the dose of 0.5 mg/kg/day. Group 2: received colchicine in the dose of 500 µg/12 h for 1 month. Group 3: received both corticosteroids in the dose of 0.5 mg/kg/day and colchicine in the dose of 500µg/12 h for 1 month. Group 4: healthy volunteers. Results A 45 pg/ml was the cut off value used to demonstrate the effect of treatment on serum IL6 in studied PC19-PF patients, with a sensitivity of 77% and 70% specificity. 180 U/ml was the cut off value used to demonstrate the effect of treatment on serum KL6, serum KL6 levels provide sensitivity of 67% and 70% specificity for the effect of treatment on serum KL6. The decrease in serum IL6 and KL6 after treatment was in group 3, followed by group 1 then group 2. Conclusion Prednisolone and colchicine were better than prednisolone alone in treatment of PC19-PF and colchicine alone showed slight improvement.

Publisher

Medknow

Reference18 articles.

1. Post-.COVID-19 pulmonary fibrosis: Novel sequelae of the current pandemic;Ambardar;J Clin Med,2021

2. Prevalence and predictors of post-COVID-19 pulmonary fibrosis;Alkhayat;EgyptJ Chest Dis Tubercul,2022

3. Serial KL-6 measurements in COVID-19 patients;d’Alessandro;Intern Emerg Med,2021

4. Post-COVID-19 pulmonary fibrosis;Mohammadi;Cureus,2022

5. Lung Fibrosis after COVID-19: Treatment Prospects;Bazdyrev;Pharmaceuticals (Basel),2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3